

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006033

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.<sup>7</sup> A61K45/00, 31/522, A61P3/00, 19/02, 19/04, 21/00, 29/00,  
43/00//C07D473/06, 473/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl.<sup>7</sup> A61K45/00, 31/522, A61P3/00, 19/02, 19/04, 21/00, 29/00,  
43/00//C07D473/06, 473/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2005  
Kokai Jitsuyo Shinan Koho 1971-2005 Toroku Jitsuyo Shinan Koho 1994-2005

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS (STN), REGISTRY (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 04/22450 A2 (FUJISAWA PHARMACEUTICAL CO LTD), 18 March, 2004 (18.03.04), Full text; CLAIM 13; P.1-2 & US 2004/22540 A1	1-14, 16
A	WO 04/16605 A1 (FUJISAWA PHARMACEUTICAL CO LTD), 26 February, 2004 (26.02.04), Full text; CLAIM 7; P.1-3 (Family: none)	1-14, 16
A	WO 03/4494 A1 (FUJISAWA PHARMACEUTICAL CO LTD), 16 January, 2003 (16.01.03), Full text; CLAIM 9; P.1-3 (Family: none)	1-14, 16

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  
12 July, 2005 (12.07.05)

Date of mailing of the international search report  
02 August, 2005 (02.08.05)

Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

# BEST AVAILABLE COPY

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006033

### C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/39451 A2 (FUJISAWA PHARMACEUTICAL CO LTD), 15 May, 2003 (15.05.03), Full text; CLAIM 8 & JP 2005-510508 A & US 2005/4134 A1 & EP 1441732 A1	1-14,16
A	MARTIN, PL et al., 'PHARMACOLOGY AND TOXICOLOGY OF THE A2A-ADENOSINE RECEPTOR AGONIST 2-[(CYCLOHEXYLMETHYLENE) HYDRAZINO]ADENOSINE (MRE-0470) IN THE RAT', DRUG DEVELOPMENT RESEARCH, (1997), Vol.42, No.2, pages 76 to 85, full text, ABSTRACT	1-14,16
A	FUJIWARA Y. et al., 'INTERACTION OF CARBAMAZEPINE AND OTHER DRUGS WITH ADENOSINE (A1 AND A2) RECEPTORS.', PSYCHOPHARMACOLOGY, (1986), Vol.90, No.3, pages 332 to 335, full text, ABSTRACT	1-14,16
A	US 2003/92668 A1 (USA), 15 May, 2003 (15.05.03), Full text & US 6211165 B	1-14,16
A	WO 03/103675 A2 (ENDACEA INC), 18 December, 2003 (18.12.03), Full text; CLAIMS- (Family: none)	1-14,16
A	WO 99/42093 A2 (UNIVERSITY OF VERGINIA), 26 August, 1999 (26.08.99), Full text; CLAIMS & US 6117878 A & AU 9928759 B	1-14,16

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006033

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15

because they relate to subject matter not required to be searched by this Authority, namely:

Claim 15 involves embodiments concerning methods for treatment of the human body by therapy and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT (continued to extra sheet)

2. ☐ Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/006033

Continuation of Box No. II-1 of continuation of first sheet (2)

and Rule 39.1(iv) of the Regulations under the PCT, to search.

&lt;&lt;With respect to scope of search&gt;&gt;

Claims 1 and 16 pertain to a preventive and/or therapeutic agent for chronic muscle/skeleton pains which contains as an active ingredient a compound having the desired property of "having antagonistic activity against an adenosine A2A receptor." The scope of each claim involves all compounds having such property. However, the compounds which are supported by the description in the meaning of Article 6 of the PCT and are disclosed in the meaning of Article 5 of the PCT are considered to be limited to an extremely small part of the compounds claimed.

It is not obvious that what compound the term "a compound having antagonistic activity against an adenosine A2A receptor" means, and the range of compounds having such property cannot be specified even when the technical common sense at the time of the filing of this application is taken into account. Consequently, the claims do not comply also with the requirement of clearness in the meaning of Article 6 of the PCT. Therefore, a search was made with respect to the relationship between an adenosine A2A receptor antagonist and chronic muscle/skeleton pains and to a preventive and/or therapeutic agent for chronic muscle/skeleton pains which contains as an active ingredient the compound which is specifically described in the description and is specified in any of claims 3-11. No search was made with respect to the direct causal relationship between an adenosine A2A receptor antagonist or any of the compounds limited in claims 3-11 and the various diseases limited in claim 14.

A.

B.

調査

最小

国際

C.

引用  
カテ

/

/

☑

\*  
「A

「E

「I

「C  
「I

国

国

様